Pulmonary complications associated with sugammadex or neostigmine in patients recovering from advanced diagnostic or interventional bronchoscopy: a retrospective two-centre analysis
- PMID: 40089395
- PMCID: PMC12226741
- DOI: 10.1016/j.bja.2025.01.039
Pulmonary complications associated with sugammadex or neostigmine in patients recovering from advanced diagnostic or interventional bronchoscopy: a retrospective two-centre analysis
Abstract
Background: Many diagnostic and interventional procedures are performed in bronchoscopy suites in high-risk patients. Minor impairment in respiratory muscle function caused by incomplete reversal of neuromuscular block can contribute to postoperative pulmonary complications (PPCs). We assessed whether there are fewer serious PPCs after diagnostic or therapeutic bronchoscopy when neuromuscular block is reversed with sugammadex rather than neostigmine.
Methods: This is a retrospective cohort study for bronchoscopy under general anaesthesia with the use of neuromuscular blockers between July 2016 and June 2022. The primary outcome was a composite of PPCs. The secondary outcome was hypoxaemia. We used inverse probability of treatment weighting (IPTW) to adjust for confounding, fitting weighted outcome regression models to evaluate the association between the treatment and outcomes.
Results: We analysed 8557 bronchoscopies across 6123 patients for the primary analysis. Adequate balance was achieved on all potential confounders after IPTW. The unweighted PPC incidence was 85/3830 (2.2%) for sugammadex and 93/4727 (2.0%) for neostigmine. The weighted PPC incidence was 2.7% for sugammadex and 1.9% for neostigmine. Sugammadex was associated with higher odds of experiencing the primary outcome of PPCs (odds ratio [OR]: 1.44; 95% confidence interval [CI]: 1.02-2.05; P=0.038), but not the secondary outcome of hypoxaemia (OR: 0.98; 95% CI: 0.81-1.20; P=0.878).
Conclusions: Sugammadex was associated with a higher risk of PPCs than neostigmine. However, the absolute difference observed (0.8%) might not be clinically meaningful. Randomised trials are needed to more accurately determine the effect of neuromuscular block reversal agent selection on respiratory complications.
Keywords: bronchoscopy; interventional pulmonology; neostigmine; neuromuscular block; postoperative pulmonary complications; sugammadex.
Copyright © 2025 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interest The authors declare that they have no conflicts of interest.
References
-
- Ernst A., Silvestri G.A., Johnstone D., American College of Chest P. Interventional pulmonary procedures: guidelines from the American college of chest physicians. Chest. 2003;123:1693–1717. - PubMed
-
- Wahidi M.M., Lamb C.R., Kovitz K., et al. Interventional pulmonology productivity, compensation, and practice benchmarks: the AABIP 2022 report. J Bronchology Interv Pulmonol. 2023;30:129–134. - PubMed
-
- de Lima A., Kheir F., Majid A., Pawlowski J. Anesthesia for interventional pulmonology procedures: a review of advanced diagnostic and therapeutic bronchoscopy. Can J Anaesth. 2018;65:822–836. - PubMed
-
- Abdelmalak B.B., Doyle D.J. Updates and controversies in anesthesia for advanced interventional pulmonology procedures. Curr Opin Anaesthesiol. 2021;34:455–463. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical